Preclinical Characterization of BI 201335, a C-Terminal Carboxylic Acid Inhibitor of the Hepatitis C Virus NS3-NS4A Protease
暂无分享,去创建一个
Peter W. White | J. Duan | M. Garneau | G. Kukolj | P. White | M. Cordingley | R. Bethell | M. Amad | G. Bolger | D. Thibeault | Jianmin Duan | Montse Llinàs-Brunet | Ma'an Amad | Richard C. Bethell | Gordon Bolger | Michael G. Cordingley | Michel Garneau | Lisette Lagacé | Diane Thibeault | George Kukolj | L. Lagacé | M. Llinàs-Brunet
[1] P. Bonneau,et al. Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection. , 2003, Angewandte Chemie.
[2] Dylan P. Hartley,et al. Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227) , 2008, Antimicrobial Agents and Chemotherapy.
[3] R. Bartenschlager,et al. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions , 1993, Journal of virology.
[4] D. Lamarre,et al. Peptide-based inhibitors of the hepatitis C virus serine protease. , 1998, Bioorganic & medicinal chemistry letters.
[5] R. De Francesco,et al. Multiple Enzymatic Activities Associated with Recombinant NS3 Protein of Hepatitis C Virus , 1998, Journal of Virology.
[6] N. Butkiewicz,et al. SCH 503034, a Mechanism-Based Inhibitor of Hepatitis C Virus NS3 Protease, Suppresses Polyprotein Maturation and Enhances the Antiviral Activity of Alpha Interferon in Replicon Cells , 2006, Antimicrobial Agents and Chemotherapy.
[7] D. Hazuda,et al. MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease , 2009, Antimicrobial Agents and Chemotherapy.
[8] D J Rance,et al. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. , 1997, The Journal of pharmacology and experimental therapeutics.
[9] L. Vrang,et al. In Vitro Activity and Preclinical Profile of TMC435350, a Potent Hepatitis C Virus Protease Inhibitor , 2009, Antimicrobial Agents and Chemotherapy.
[10] M. Bös,et al. Blunting the Swiss army knife of hepatitis C virus: inhibitors of NS3/4A protease. , 2006, Progress in medicinal chemistry.
[11] D. Lamarre,et al. Sensitivity of NS3 Serine Proteases from Hepatitis C Virus Genotypes 2 and 3 to the Inhibitor BILN 2061 , 2004, Journal of Virology.
[12] X. Forns,et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. , 2004, Gastroenterology.
[13] D. Lamarre,et al. Studies on the C-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease. , 1998, Bioorganic & medicinal chemistry letters.
[14] M. Houghton,et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. , 1989, Science.
[15] Christophe Combet,et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes , 2005, Hepatology.
[16] Charles M. Rice,et al. Highly Permissive Cell Lines for Subgenomic and Genomic Hepatitis C Virus RNA Replication , 2002, Journal of Virology.
[17] M. Prichard,et al. A three-dimensional model to analyze drug-drug interactions. , 1990, Antiviral research.
[18] G. Kukolj,et al. Identification of a lipid kinase as a host factor involved in hepatitis C virus RNA replication. , 2009, Virology.
[19] D. Lamarre,et al. An NS3 Serine Protease Inhibitor Abrogates Replication of Subgenomic Hepatitis C Virus RNA* , 2003, Journal of Biological Chemistry.
[20] R. Cortese,et al. Product inhibition of the hepatitis C virus NS3 protease. , 1998, Biochemistry.
[21] M. Murcko,et al. Crystal Structure of the Hepatitis C Virus NS3 Protease Domain Complexed with a Synthetic NS4A Cofactor Peptide , 1996, Cell.
[22] R. Bartenschlager,et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome , 2005, Nature Medicine.
[23] B. Kronenberger,et al. Current and future treatment options for HCV. , 2009, Annals of hepatology.
[24] J. Glass,et al. P4 and P1' optimization of bicycloproline P2 bearing tetrapeptidyl alpha-ketoamides as HCV protease inhibitors. , 2004, Bioorganic & medicinal chemistry letters.
[25] A. Kwong,et al. Preclinical Profile of VX-950, a Potent, Selective, and Orally Bioavailable Inhibitor of Hepatitis C Virus NS3-4A Serine Protease , 2006, Antimicrobial Agents and Chemotherapy.
[26] Weiying Yang,et al. Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: , 2006, Journal of medicinal chemistry.
[27] T. Chou,et al. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.
[28] Y. Cheng,et al. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.
[29] Ting-Chao Chou,et al. Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.
[30] M. Manns,et al. Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. , 2011, Journal of hepatology.
[31] M. Massariol,et al. Protease and helicase activities of hepatitis C virus genotype 4, 5, and 6 NS3-NS4A proteins. , 2010, Biochemical and biophysical research communications.
[32] M. Vita,et al. Stability, pKa and plasma protein binding of roscovitine. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[33] M. Garneau,et al. Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335). , 2010, Journal of medicinal chemistry.
[34] D. Lavanchy,et al. The global burden of hepatitis C , 2009, Liver international : official journal of the International Association for the Study of the Liver.
[35] R. Bartenschlager,et al. Replication of hepatitis C virus. , 2000, The Journal of general virology.
[36] Steven R. LaPlante,et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus , 2003, Nature.
[37] H. Parge,et al. The Crystal Structure of Hepatitis C Virus NS3 Proteinase Reveals a Trypsin-like Fold and a Structural Zinc Binding Site , 1996, Cell.
[38] Ann D. Kwong,et al. VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells , 2006, Antimicrobial Agents and Chemotherapy.
[39] R. Bartenschlager,et al. Complex formation between the NS3 serine-type proteinase of the hepatitis C virus and NS4A and its importance for polyprotein maturation , 1995, Journal of virology.
[40] H. Wedemeyer,et al. Antiviral efficacy of NS3‐serine protease inhibitor BILN‐2061 in patients with chronic genotype 2 and 3 hepatitis C , 2005, Hepatology.
[41] D. Burton,et al. Robust hepatitis C virus infection in vitro. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[42] P. Artursson,et al. Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. , 1990, Journal of pharmaceutical sciences.